- Home
- APCX vs EDSA Comparison
APCX vs EDSA Comparison
Compare APCX & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APCX
- EDSA
- Stock Information
- Founded
- APCX 2006
- EDSA 2015
- Country
- APCX United States
- EDSA Canada
- Employees
- APCX N/A
- EDSA N/A
- Industry
- APCX Finance: Consumer Services
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- APCX Finance
- EDSA Health Care
- Exchange
- APCX Nasdaq
- EDSA Nasdaq
- Market Cap
- APCX N/A
- EDSA 6.1M
- IPO Year
- APCX N/A
- EDSA N/A
- Fundamental
- Price
- APCX $0.60
- EDSA $1.73
- Analyst Decision
- APCX
- EDSA Strong Buy
- Analyst Count
- APCX 0
- EDSA 1
- Target Price
- APCX N/A
- EDSA $21.00
- AVG Volume (30 Days)
- APCX 10.7M
- EDSA 30.8K
- Earning Date
- APCX 11-14-2024
- EDSA 02-07-2025
- Dividend Yield
- APCX N/A
- EDSA N/A
- EPS Growth
- APCX N/A
- EDSA N/A
- EPS
- APCX N/A
- EDSA N/A
- Revenue
- APCX $365,000.00
- EDSA N/A
- Revenue This Year
- APCX $1,315.48
- EDSA N/A
- Revenue Next Year
- APCX N/A
- EDSA N/A
- P/E Ratio
- APCX N/A
- EDSA N/A
- Revenue Growth
- APCX N/A
- EDSA N/A
- 52 Week Low
- APCX $0.31
- EDSA $1.55
- 52 Week High
- APCX $2.30
- EDSA $5.99
- Technical
- Relative Strength Index (RSI)
- APCX 60.21
- EDSA 31.51
- Support Level
- APCX $0.36
- EDSA $1.73
- Resistance Level
- APCX $1.49
- EDSA $1.99
- Average True Range (ATR)
- APCX 0.14
- EDSA 0.19
- MACD
- APCX 0.02
- EDSA 0.02
- Stochastic Oscillator
- APCX 24.32
- EDSA 18.00
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.